• Portuguese
    Spanish
Loading...

Cristália's Highlights

Cristália é reconhecido pela oitava vez no prêmio Líderes da Saúde

Grupo Mídia reconhece as empresas mais relevantes para a cadeia da Saúde brasileira

READ MORE
Fundador e presidente do Cristália toma posse na ACFB Programa Valorização do Cristália premia colaboradores por ideias de melhorias operacionais Cristália marca presença no 69º Congresso Brasileiro de Anestesiologia (CBA) Frente Parlamentar Mista de Saúde discute o cenário da saúde mental no Brasil
SEE ALL NEWS

Pharmaceuticals

  • Indústria farmacêutica
  • Lider em anestésicos

Pharmaceuticals

Pharmaceutical Oncologic

RD&I

PPAs

APIs Plant

Biotechnology Plant

APIs for Oncology

Rio do Peixe

Biotechnology Plant – Anaerobics

Water Treatment

A.D.

VIRTUAL TOUR

Health Industrial Park | Itapira | SP

Cristália is one of the largest and most complete pharmaceutical laboratories in Brazil. Learn more about our complex.

Complexo Industrial para a Saúde - Itapira - SP

Pharmaceuticals

Itapira - SP

Pharmaceutical Oncologic

Itapira - SP

RD&I

Itapira - SP

PPAs

Itapira - SP

APIs Plant

Itapira - SP

Biotechnology Plant

Itapira - SP

APIs for Oncology

Itapira - SP

Rio do Peixe

Itapira - SP

Biotechnology Plant – Anaerobics

Itapira - SP

Water Treatment

Itapira - SP

A.D.

Itapira - SP

PIONEER IN BIOTECHNOLOGY

The Premier Brazilian Biotechnolofy Company

Cristália is a pioneer in Biotechnology. For about 20 years, the company has been conducting research on new molecules and products, and now owns two manufacturing plants that have been certified by Anvisa with Good Manufacturing Practices (GMP) certificates for biological pharmaceutical inputs. Our Biotechnology Industrial Park, and the Anaerobic Bacteria Plant, both located at Itapira Industrial Park, in São Paulo, are among the most modern ones around the world.

Pharmaceutical inputs 130 Patents granted Research & Development

  • Pharmaceutical inputs

    While Brazilian pharmaceutical industry imports about 90% of the Active Pharmaceutical Inputs (APIs) employed in drugs manufacturing, Cristália produces 60% of the APIs it needs to manufacture its drugs.

  • 130 Patents granted

    Cristália has been granted with 130 Patents in Brazil, UE, United States, and other 11 countries. Included in those patents are the anesthetics S-ketamine, a drug designed to treat burn injuries - Alimax, and Helleva, for erectile dysfunction.

  • Research & Development

    Cristália invests about 8% of its annual revenues in research and development activities. In its RD&I-dedicated plant located at Itapira Industrial Park, in the state of São Paulo, around 30 new drug projects are under development, and 60% of these are breakthroughs.

Pharmaceutical inputs 130 Patents granted Research & Development

TIMELINE

Cristália's Timeline

Important Facts in the History of Cristália

Cristália's Timeline

Cristália launches campaign on cyberbehaviors

Cristália's campaign "Cancel the Stigma and Not People – Technology and the Impact on Mental Health" comes at a critical moment, when Brazil occupies the second place in the global ranking of screen use. The purpose of this campaign is to challenge and reshape our approach towards new technologies, recognizing the significant impacts they have on our mental health.

2024

Cristália launches campaign on cyberbehaviors

Cristália's campaign "Cancel the Stigma and Not People – Technology and the Impact on Mental Health" comes at a critical moment, when Brazil occupies the second place in the global ranking of screen use. The purpose of this campaign is to challenge and reshape our approach towards new technologies, recognizing the significant impacts they have on our mental health.

2024
Cristália launches campaign on cyberbehaviors
Cristália's campaign "Cancel the Stigma and Not People – Technology and the Impact on Mental Health" comes at a critical moment, when Brazil occupies the second place in the global ranking of screen use. The purpose of this campaign is to challenge and reshape our approach towards new technologies, recognizing the significant impacts they have on our mental health.
Laboratório Cristália
2023
Granted a patent in the US
Granted a patent in the US for the process of inactivating liquid waste from the API and APIs for Oncology plants, which makes waste treatment safer and more efficient, at a lower cost and without CO2 emissions.
2021
Acquisition of Montes Claros's plant
Acquisition of a manufacturing plant at the Industrial District located in the city of Montes Claros (MG), where Laboratório Cristália's new pharmaceutical plant will be opened.
+

2024

2024
Cristália launches campaign on cyberbehaviors
Cristália's campaign "Cancel the Stigma and Not People – Technology and the Impact on Mental Health" comes at a critical moment, when Brazil occupies the second place in the global ranking of screen use. The purpose of this campaign is to challenge and reshape our approach towards new technologies, recognizing the significant impacts they have on our mental health.
2023
Granted a patent in the US
Granted a patent in the US for the process of inactivating liquid waste from the API and APIs for Oncology plants, which makes waste treatment safer and more efficient, at a lower cost and without CO2 emissions.
2021
Acquisition of Montes Claros's plant
Acquisition of a manufacturing plant at the Industrial District located in the city of Montes Claros (MG), where Laboratório Cristália's new pharmaceutical plant will be opened.
2020
Granting of the 112th paten
Cristália was granted with its 112th patent. These 4 new patents refer to DI (Industrial Design) for eyedrops.
2019
The First Plant of APIs for Oncology was launched
In August 2019, with the presence of the Brazilian President, Jair Messias Bolsonaro, Laboratório Cristália launched the first high-powered APIs for Oncology Plant in Latin America.
2018
Latinofarma merger
On January 1st, 2018, the affiliated company Latinofarma was officially merged with Cristália. The company will operate as the Ophthalmology division of Cristália. Latinofarma was acquired in 2015 by Cristália Group. Its portfolio includes over 20 products in about 40 different supplies, including: artificial tears, anti-inflammatory agents and associations, ophthalmic ointments, and diagnostic tests, meeting the distinctive prescription needs of clinical and operating ophthalmologists.
2017
Opening of
Plant IV
In September 2017, Cristália opened its Plant IV, where the Distribution Center is located. The event was attended by the Governor of the state of São Paulo as well as by many government authorities. The Distribution Center is the result of investments on the order of $ 400 million BRL, and has a building area of 16,000 m² on a 120,000m² land.
2016
Collagenase API
After 15 years of studies and investments in research, Cristália was granted by Anvisa (Brazilian regulatory agency) with the registration of the first biotechnological Active Pharmaceutical Input obtained from Brazilian biodiversity: the collagenase API. As a result of this, for the first time in history, Brazil is able to export biotechnology, eliminating the need of importing collagenase.
2015
Acquisition of Latinofarma
With the acquisition of Latinofarma, Cristália strengthened its presence in the segment of ophthalmology, now counting on a comprehensive portfolio of artificial tears and prescription eye drops.
2014
Biotechnology
Opening of the second Biotechnology plant, the first in the class of Biotechnology – Anaerobics in the country. It's in that plant that the API Collagenase is manufactured, a substance vertically developed by the Company, using 100% Brazilian science. This is the first biotechnological drug obtained from Brazilian biodiversity.
2013
Expansion of the Industrial Park
Opening of the first Biotechnology plant, with an area of 1.7 thousand m², dedicated to research and development of biologicals. This is the first private biologicals plant in Brazil, focusing the manufacturing of monoclonal antibodies.
2012
Acquisition of Unit VIII
Unit VIII was acquired by Cristália Group, and now offers three product portfolios to the market: pharmaceuticals, hospital disposables, and hemodyalisis materials. There is about 376 employees and a sales team with representatives in key Brazilian cities.

CRISTÁLIA BY THE NUMBERS

Innovation for society

Organizations that want to be winners serving society and ensuring the sustainability of the planet must be clear about the mission, vision and values that should guide all projects, day-to-day work and the relationship with stakeholders.

19

PDPS WITH FEDERAL GOVERNMENT

To transfer technology to public laboratories

130

PATENTS OWNED

And 251 patent application request

350

DRUGS

In over 500 supply forms

300

REGISTERED PRODUCTS ABROAD

Cristália also exports to more than 30 countries

19

PDPS WITH FEDERAL GOVERNMENT

To transfer technology to public laboratories

FOLLOW CRISTÁLIA

Our History in Motion

SEE ALL VIDEOS

Watch our videos

Cookies

Our website uses cookies to make your browsing experience better. When continuing your browsing, your agreement with our policy of using them is considered. For more information, see our Cookie Policy.

AGREE
SAC
0800 701 1918